首页AIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
市场资讯
财务信息
损益表
收入
净收入
(USD) | 2024年3月info | 年同比变化 |
---|---|---|
收入 | 4.00万 | -18.37% |
经营支出 | 576.60万 | 32.73% |
净收入 | -581.70万 | -58.89% |
净利润率 | -1.45万 | -94.64% |
每股收益 | -0.12 | -41.84% |
息税折旧摊销前利润 | -567.60万 | -33.62% |
有效税率 | — | — |
资产负债表
总资产
负债总额
(USD) | 2024年3月info | 年同比变化 |
---|---|---|
现金及短期投资 | 1094.20万 | -64.53% |
总资产 | 1618.90万 | -56.79% |
负债总额 | 1136.30万 | 359.48% |
权益总额 | 482.60万 | — |
发行在外的股份 | 5128.14万 | — |
市净率 | 4.56 | — |
资产回报率 | -80.60% | — |
资本回报率 | -149.88% | — |
现金流
现金净变动
(USD) | 2024年3月info | 年同比变化 |
---|---|---|
净收入 | -581.70万 | -58.89% |
来自运营的现金 | -481.50万 | -30.84% |
投资现金 | -15.80万 | -102.56% |
融资现金 | 282.90万 | 2,729.00% |
现金净变动 | -214.40万 | 41.39% |
自由现金流 | -276.18万 | -22.62% |
简介
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
成立时间
1966
员工数量
27